Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00984165 · OUTCOME

Number of Participants With Adverse Events

Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation · Source last updated 2018-05-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Date treatment consent signed to date off study, approximately 36 months.

What was measured

Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module.

Groups in this outcome

Donor Lymphocyte Infusion/Radiation

Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).

Radiation/No Donor Lymphocyte Infusion

Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).

Donor Lymphocyte Infusion - Control

Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.

Donor Lymphocyte Infusion - Donor

Healthy subjects who donated lymphocytes for infusion on a treatment Arm.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Donor Lymphocyte Infusion/Radiation9
Radiation/No Donor Lymphocyte Infusion1
Donor Lymphocyte Infusion - Control4
Donor Lymphocyte Infusion - Donor4

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Donor Lymphocyte Infusion/Radiation9Not reportedNot reportedNot reportedNot reported
Radiation/No Donor Lymphocyte Infusion1Not reportedNot reportedNot reportedNot reported
Donor Lymphocyte Infusion - Control4Not reportedNot reportedNot reportedNot reported
Donor Lymphocyte Infusion - Donor0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        4
      4. group Id
        OG003
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      4
    units
    Participants
description
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module.
groups
  1. description
    Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
    id
    OG000
    title
    Donor Lymphocyte Infusion/Radiation
  2. description
    Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
    id
    OG001
    title
    Radiation/No Donor Lymphocyte Infusion
  3. description
    Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
    id
    OG002
    title
    Donor Lymphocyte Infusion - Control
  4. description
    Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
    id
    OG003
    title
    Donor Lymphocyte Infusion - Donor
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Date treatment consent signed to date off study, approximately 36 months.
title
Number of Participants With Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice